Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

# CCT251236

## Catalog No: tcsc6956

### Available Sizes

**Size:** 1mg

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

### Specifications

**CAS No:**
1693731-40-6

**Formula:**
$C_{32}H_{32}N_4O_5$

**Pathway:**
Metabolic Enzyme/Protease;Cell Cycle/DNA Damage

**Target:**
HSP;HSP

**Purity / Grade:**
>98%

**Solubility:**
DMSO : ≥ 150 mg/mL (271.43 mM)

**Observed Molecular Weight:**
552.62

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

## Product Description

CCT251236 is an orally available pirin ligand from a heat shock transcription factor 1 (hsf1) phenotypic screen with an **$IC_{50}$** of 19 nM for inhibition of HSF1-mediated **HSP72** induction.

IC50 & Target: IC50: 19 nM (HSF1-mediated HSP72 induction)[1]

***In Vitro:*** CCT251236 displays the desired balance of *in vitro* properties, while maintaining excellent cellular activity with an $IC_{50}$ of 19 nM. The free $GI_{50}$ in SK-OV-3 cells is 1.1 nM. Western blotting confirms that CCT251236 blocks the HSF1-mediated induction of both HSP72 and HSP27 as representative heat shock proteins, following treatment with the HSP90 inhibitor 17AAG. Also, qPCR analysis demonstrates that CCT251236 inhibits the induction of HSP72 at the mRNA level, clearly blocking the induction of HSPA1A gene expression with an $IC_{50}$ of 40 nM[1].

***In Vivo:*** CCT251236 possesses low total blood clearance (10% hepatic blood flow) and moderate oral bioavailability, with a half-life sufficient to allow once-a-day dosing. Clear therapeutic efficacy is observed with CCT251236, with a tumor growth inhibition of 70% based on final tumor volumes[1].